Companion Diagnostics Spark Pharma Deals - But Still Mostly For Cancer
Executive Summary
An inaugural review of the diagnostics sector newly published by PricewaterhouseCoopers contends that growing interest in personalized medicine is a key factor driving partnering deals between pharmaceutical companies and diagnostics developers
You may also be interested in...
Companion Diagnostics Move Toward Mainstream Drug Development
With FDA planning to release guidelines on companion diagnostics by year's end, private sector activity around biomarkers appears ready to accelerate. Pharma companies are taking different strategies to incorporate companion diagnostics into their drug development programs, and experimenting with different applications for co-developed products. The relationship between Pharma and diagnostics companies is evolving, with Pharma leading the way. The pace of dealmaking is picking up, but in negotiating partnerships, both sides are still struggling with how to reconcile their different business models, cost structures, and appetites for risk.
Companion Diagnostics Move Toward Mainstream Drug Development
With FDA planning to release guidelines on companion diagnostics by year's end, private sector activity around biomarkers appears ready to accelerate. Pharma companies are taking different strategies to incorporate companion diagnostics into their drug development programs, and experimenting with different applications for co-developed products. The relationship between Pharma and diagnostics companies is evolving, with Pharma leading the way. The pace of dealmaking is picking up, but in negotiating partnerships, both sides are still struggling with how to reconcile their different business models, cost structures, and appetites for risk.
Biomarkers: Venture Capitalists Press FDA For Better Development Incentives
FDA should declare that products with a companion diagnostic should be eligible for accelerated approval, according to Marc Boutin, executive director of the National Health Council